Endometrial pathology in postmenopausal tamoxifen treatment: Comparison between gynaecologically symptomatic and asymptomatic breast cancer patients

Ilan Cohen, Eran Perel, Dov Flex, Ron Tepper, Marco M. Altaras, Mario Cordoba, Yoram Beyth

Research output: Contribution to journalArticlepeer-review

Abstract

Aims - To evaluate whether endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic rather than in gynaecologically asymptomatic postmenopausal breast cancer patients with tamoxifen treatment; and to evaluate the possible influence of various clinical factors on the incidence of endometrial pathology. Methods - Endometrial histological findings, transvaginal ultrasonographic endometrial thickness, demographic characteristics, health habits, and risk factors for endometrial cancer were compared between 14 gynaecologically symptomatic (group I) and 224 gynaecologically asymptomatic (group II) postmenopausal breast cancer patients with tamoxifen treatment. Results - Overall, 28.6% of the study population had endometrial pathology. The incidence of overall positive endometrial histological findings was significantly higher in group I than in group II (92.9% v 24.6%, p < 0.0001). Atrophic endometrium was more common in group II than in group I (75.3% v 7.1%, p < 0.0001). Most other endometrial pathology was significantly more common in group I than in group II (endometrial hyperplasia, 35.7% v 5.6%, p < 0.0001; endometrial polyps, 35.7% v 13.4%, p < 0.0111; endometrial carcinoma, 21.5% v 0.9%, p < 0.0001). Endometrial pathology appeared considerably later in the gynaecologically asymptomatic patients than in gynaecologically symptomatic patients (p = 0.0002). Vaginal bleeding or spotting occurred exclusively in group I. The incidence of endometrial pathology in the entire study population was consistent with that reported elsewhere, and higher than that reported for healthy postmenopausal women. Conclusions - Endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic postmenopausal breast cancer patients with tamoxifen treatment, and after a shorter duration of time, than in gynaecologically asymptomatic patients.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalJournal of Clinical Pathology
Volume52
Issue number4
DOIs
StatePublished - 1999

Keywords

  • Endometrial pathology
  • Tamoxifen

Fingerprint

Dive into the research topics of 'Endometrial pathology in postmenopausal tamoxifen treatment: Comparison between gynaecologically symptomatic and asymptomatic breast cancer patients'. Together they form a unique fingerprint.

Cite this